August 19, 2021
OncoBone is excited to announce partnership with the VYANTbio company vivoPharm, a preclinical CRO that provides proprietary oncology and immuno-oncology services, toxicology testing and bioanalytical analysis to the biotechnology and pharmaceutical industries.
The goal of the partnership includes OncoBone to expand visibility and client-base of vivoPharm especially in bone metastasis models, the core expertise area of OncoBone. The partnership also includes OncoBone to help vivoPharm in the development and marketing of additional new bone metastasis models.
Tiina Kähkönen, CSO of OncoBone says: “We are very excited to work with vivoPharm. A member of vivoPharm was involved in research that resulted in developing intratibial injection, the core technique used in many bone metastasis models. We are delighted to work with a true global leader who shares our passion to advance preclinical testing of therapies for bone metastatic disease.”
Melanie Keller, vivoPharm’s Division Head in Europe adds: “We are impressed about the scientific expertise of OncoBone in bone metastasis models. This together with their strong expertise in marketing and sales activities of bone metastasis models makes OncoBone a perfect partner for vivoPharm in order to expand visibility of both companies.”
If you are interested to learn more,
see our services or contact us directly.